Exabis Library
Welcome to the e-CCO Library!
P399: Vedolizumab therapy results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish vedolizumab consortium
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P400 Understanding the impact of TNF-α antagonists on the severity of non-melanoma skin cancer in inflammatory bowel disease and the consequences for therapy
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P400: Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P400: Bowel ultrasonography, a non invasive easy-to-use method to predict the need to step-up therapy in inflammatory bowel disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P400: Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P400: Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P400: Identifying Nutritional targets in Crohn's disease: INTICO1: a time-limited trial of exclusive enteral nutrition during adult CD remission
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P400: Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P401 Sarcopenia in children and young adults with primary sclerosing cholangitis and IBD
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P401: Anti-TNF treatments in Crohn's disease and improvement in work productivity and quality of life: an observational study from Turkey
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P401: Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P401: Concomitant azathioprine treatment effects vedolizumab treatment persistence in Crohn's Disease but not in Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P401: Confocal laser endomicroscopy predicts response in patients with acute inflammatory bowel disease undergoing anti-integrin therapy with vedolizumab
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P401: Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodies
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P401: Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P401: Tofacitinib tissue exposure correlates with endoscopic outcome
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P402 Prediction of emergency department re-visit among Crohn’s disease patients: a retrospective study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P402: A novel high-dose mesalazine tablet is as effective as conventional low-dose mesalazine tablets in inducing remission in patients with mildly to moderately active ulcerative colitis (UC): A double-blind, double-dummy, multicentre, randomised trial
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P402: A Pilot Study on the Effect of Colesevelam on the Microbiome in Primary Terminal Ileal Resected Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P402: Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's disease: outcomes and risk factors associated with relapse
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM